Latest news with #Parvus
Yahoo
7 days ago
- Business
- Yahoo
Novo Nordisk A/S (NVO): 'How Could They Be So Far Behind?,' Wonders Jim Cramer
Novo Nordisk A/S (NYSE:NVO) is one of the . Novo Nordisk A/S (NYSE:NVO) is a Danish pharmaceutical giant that is a key player in the weight loss drug market. The firm's shares have lost 15.7% year-to-date. Novo Nordisk A/S (NYSE:NVO) has struggled primarily due to investor fears about Eli Lilly overtaking the firm in the weight loss drug market. Other news, such as a surprise departure of the firm's CEO hasn't helped the stock pare back its losses either. Novo Nordisk A/S (NYSE:NVO)'s stock lost 6% in March after its CagriSema weight loss drug fell short of the firm's estimates. While it had expected the drug to help users lose 25% of their body weight, the trials led to a 15.7% weight reduction. Cramer commented on activist investor Parvus taking a stake in the company: [On activist fund Parvus building a stake in the company] How could they be so far behind? You know they were first, they were first mover. And then Lilly came along, Lilly by the way, still a great stock. But maybe this is going to shake up Novo. In his previous comments about Novo Nordisk A/S (NYSE:NVO), Cramer commented on the firm in the context of Eli Lilly: An elderly couple receiving insulin from a pharmacist, representing healthcare company's successful pharmaceutical products. 'Okay, Eli Lilly. We bought some just the other day for the Charitable Trust. Why did we do that? Because it's down very big and yet it's been beating Novo Nordisk over and over and over again. So I just think this is a decent level to start a position if you don't have any.' While we acknowledge the potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.
Yahoo
09-06-2025
- Business
- Yahoo
Why Novo Nordisk Stock Eked Out a Win on Monday
A media report stated that an activist investor is accumulating a stake in the Wegovy maker. According to the article, that investor aims to influence the company's choice of a chief executive. 10 stocks we like better than Novo Nordisk › Wegovy and Ozempic maker Novo Nordisk (NYSE: NVO) saw its stock price tick up slightly on Monday, on a media report about the possible entry of an activist investor. Market players cautiously bid the shares a little more than 1% higher on the news. Although this wasn't a giant gain, it was sufficient to top the S&P 500 index's basically flat-line performance. Citing unnamed "people with knowledge of the details," the Financial Times reported Monday that London-based activist hedge fund Parvus Asset Management is accumulating stock in Novo Nordisk. The FT's sources said that the goal is to influence the company's choice of CEO, as its longtime leader Lars Fruergaard Jørgensen stepped down from the post last month. A replacement has not yet been found. It wasn't immediately clear how much of a stake Parvus has managed to amass. Novo Nordisk is based in Denmark and listed on that country's main stock exchange. Per Danish securities law, a strategic investor need not disclose the size of a stake if its holding is below 5% of a company's equity. While Parvus isn't a well-known activist investor to many Americans, it has been actively involved in European companies. Among the businesses in which it has taken a stake are discount airline Ryanair and storied Italian bank UniCredit. Neither Novo Nordisk nor Parvus has yet commented on the FT article. Activist investors often circle the water when a company is struggling and its share price sinks. That's been the case with Novo Nordisk, which has seen setbacks in its drug development activities lately while facing intensifying competition for weight-loss drug Wegovy. I don't think investors should trade on the basis of whether an activist like Parvus will enter the company and begin agitating once it's there. The situation is worth monitoring, though, as a determined activist can indeed shape the strategy of a business. Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 173% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Why Novo Nordisk Stock Eked Out a Win on Monday was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
